We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SRP9 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
315.3
Number of samples
141
Samples
Sample
Description
TPM
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
719.5
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
683.3
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
598.4
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
533.5
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
501.4
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
488.3
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
488.1
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
484.8
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
478.1
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
466.3
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
466.2
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
455.7
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
441.9
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
430.6
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
424.2
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
420.7
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
415.5
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
413.5
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
413.5
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
413.3
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
412.9
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
409.9
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
408.5
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
404.8
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
404.1
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
391.9
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
390.2
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
379.8
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
376.7
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
375.0
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
374.4
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
373.9
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
373.4
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
365.3
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
362.1
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
360.8
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
359.9
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
349.6
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
342.5
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
340.6
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
337.9
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
334.6
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
334.2
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
333.5
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
331.7
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
329.7
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
328.7
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
328.7
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
328.2
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
327.6
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
326.4
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
325.1
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
322.0
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
321.9
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
321.1
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
320.5
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
320.1
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
317.1
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
316.0
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
316.0
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
315.5
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
314.6
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
313.8
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
311.3
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
310.9
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
310.2
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
308.8
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
308.7
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
307.9
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
307.4
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
306.8
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
303.0
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
300.7
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
300.2
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
299.6
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
297.6
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
290.7
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
290.7
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
287.6
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
286.0
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
285.2
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
284.2
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
283.7
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
283.3
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
279.3
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
276.8
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
276.3
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
275.4
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
274.3
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
273.3
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
271.2
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
271.0
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
269.3
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
268.9
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
267.1
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
267.0
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
264.7
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
264.5
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
264.4
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
264.3
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
264.3
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
264.0
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
263.2
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
262.1
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
258.8
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
253.3
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
249.7
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
249.4
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
247.0
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
246.7
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
245.1
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
243.5
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
243.5
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
243.3
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
242.8
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
241.9
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
240.7
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
240.0
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
239.0
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
237.5
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
232.9
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
231.9
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
230.7
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
229.3
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
220.8
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
220.4
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
220.1
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
216.9
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
210.3
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
208.9
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
203.3
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
201.8
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
200.4
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
199.2
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
188.7
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
181.6
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
173.6
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
171.8
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SRP9 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
133.4
Number of samples
58
Samples
Sample
Description
TPM
AK002
N, NA, stage:NA, dead, 570 days
271.5
AK156
N, NA, stage:NA, dead, 330 days
269.2
AK117
N, NA, stage:NA, dead, 210 days
257.2
AK074
N, NA, stage:NA, alive, 300 days
209.3
AK142
N, NA, stage:NA, alive, 90 days
185.1
AK139
N, NA, stage:NA, dead, 270 days
184.3
AK081
N, NA, stage:NA, dead, 180 days
184.2
AK183
N, NA, stage:NA, alive, 360 days
181.2
AK231
N, NA, stage:NA, dead, 240 days
177.5
AK133
N, NA, stage:NA, dead, 360 days
176.8
AK051
N, NA, stage:NA, dead, 360 days
161.8
AK167
N, NA, stage:NA, dead, 180 days
159.2
AK199
N, NA, stage:NA, alive, 1860 days
156.0
AK030
N, NA, stage:NA, dead, 120 days
154.5
AK236
N, NA, stage:NA, dead, 360 days
149.7
AK098
N, NA, stage:NA, dead, 660 days
147.5
AK041
N, NA, stage:NA, alive, 810 days
146.9
AK043
N, NA, stage:NA, alive, 660 days
144.4
AK124
N, NA, stage:NA, alive, 1920 days
144.1
AK006
N, NA, stage:NA, dead, 360 days
141.9
AK158
N, NA, stage:NA, dead, 360 days
140.6
AK015
N, NA, stage:NA, alive, 720 days
140.1
AK099
N, NA, stage:NA, dead, 420 days
138.1
AK071
N, NA, stage:NA, dead, 540 days
136.1
AK216
N, NA, stage:NA, dead, 360 days
135.8
AK173
N, NA, stage:NA, dead, 180 days
134.4
AK123
N, NA, stage:NA, dead, 180 days
133.8
AK213
N, NA, stage:NA, alive, 2010 days
133.4
AK055
N, NA, stage:NA, dead, 240 days
130.7
AK149
N, NA, stage:NA, dead, 420 days
128.5
AK003
N, NA, stage:NA, dead, 600 days
128.1
AK066
N, NA, stage:NA, alive, 960 days
123.4
AK049
N, NA, stage:NA, dead, 180 days
121.3
AK165
N, NA, stage:NA, alive, 360 days
120.9
AK035
N, NA, stage:NA, dead, 210 days
118.4
AK089
N, NA, stage:NA, dead, 330 days
116.9
AK153
N, NA, stage:NA, dead, 240 days
116.7
AK205
N, NA, stage:NA, dead, 120 days
112.1
AK079
N, NA, stage:NA, dead, 210 days
111.3
AK226
N, NA, stage:NA, dead, 360 days
111.1
AK188
N, NA, stage:NA, alive, 420 days
108.7
AK091
N, NA, stage:NA, dead, 210 days
104.0
AK005
N, NA, stage:NA, dead, 240 days
103.8
AK100
N, NA, stage:NA, alive, 960 days
102.4
AK134
N, NA, stage:NA, dead, 360 days
101.1
AK085
N, NA, stage:NA, alive, 660 days
98.9
AK227
N, NA, stage:NA, alive, 300 days
97.9
AK103
N, NA, stage:NA, alive, 1320 days
97.8
AK178
N, NA, stage:NA, dead, 240 days
96.8
AK072
N, NA, stage:NA, dead, 150 days
95.8
AK053
N, NA, stage:NA, dead, 300 days
93.0
AK195
N, NA, stage:NA, dead, 390 days
89.9
AK068
N, NA, stage:NA, alive, 360 days
86.1
AK102
N, NA, stage:NA, alive, 1740 days
80.4
AK088
N, NA, stage:NA, dead, 360 days
72.9
AK218
N, NA, stage:NA, dead, 180 days
72.4
AK185
N, NA, stage:NA, alive, 330 days
58.9
AK076
N, NA, stage:NA, alive, 660 days
44.7
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0078580003
Tumor
0.9
CPT0218770003
Tumor
0.9
CPT0217190003
Tumor
0.7
CPT0218830004
Tumor
0.6
CPT0161730003
Tumor
0.6
CPT0189570004
Tumor
0.6
CPT0168080003
Tumor
0.5
CPT0190240004
Tumor
0.5
CPT0206670004
Tumor
0.5
CPT0093450003
Tumor
0.4
CPT0206230003
Tumor
0.4
CPT0127480003
Tumor
0.4
CPT0217000004
Tumor
0.3
CPT0207090003
Tumor
0.3
CPT0218330004
Tumor
0.3
CPT0224390004
Tumor
0.3
CPT0206780003
Tumor
0.3
CPT0218690004
Tumor
0.3
CPT0208980003
Tumor
0.2
CPT0182500003
Tumor
0.2
CPT0217430008
Tumor
0.2
CPT0189250003
Tumor
0.2
CPT0217710008
Tumor
0.2
CPT0171580008
Tumor
0.2
CPT0201710003
Tumor
0.2
CPT0087680003
Tumor
0.2
CPT0162140003
Tumor
0.2
CPT0218890004
Tumor
0.2
CPT0162100003
Tumor
0.2
CPT0206560003
Tumor
0.1
CPT0217100003
Tumor
0.1
CPT0224600003
Tumor
0.1
CPT0182550003
Tumor
0.1
CPT0182580003
Tumor
0.1
CPT0167530003
Tumor
0.1
CPT0218960004
Tumor
0.1
CPT0225730003
Tumor
0.0
CPT0064890003
Tumor
0.0
CPT0205780003
Tumor
0.0
CPT0205570003
Tumor
0.0
CPT0168270003
Tumor
0.0
CPT0218670003
Tumor
0.0
CPT0224330003
Tumor
0.0
CPT0089150003
Tumor
0.0
CPT0189460003
Tumor
0.0
CPT0123530003
Tumor
0.0
CPT0224540004
Tumor
0.0
CPT0093510003
Tumor
0.0
CPT0167750004
Tumor
0.0
CPT0205450004
Tumor
0.0
CPT0206000004
Tumor
-0.1
CPT0167640003
Tumor
-0.1
CPT0064650003
Tumor
-0.1
CPT0125570003
Tumor
-0.1
CPT0127420003
Tumor
-0.1
CPT0168380003
Tumor
-0.1
CPT0205890003
Tumor
-0.1
CPT0219080004
Tumor
-0.1
CPT0207030003
Tumor
-0.1
CPT0104330003
Tumor
-0.1
CPT0092440003
Tumor
-0.1
CPT0125220003
Tumor
-0.1
CPT0168830003
Tumor
-0.1
CPT0225760003
Tumor
-0.1
CPT0189850004
Tumor
-0.1
CPT0071100003
Tumor
-0.1
CPT0168480003
Tumor
-0.2
CPT0190360004
Tumor
-0.2
CPT0168720003
Tumor
-0.2
CPT0189750004
Tumor
-0.2
CPT0204390003
Normal
-0.2
CPT0204330003
Normal
-0.2
CPT0104220003
Tumor
-0.2
CPT0217060003
Tumor
-0.2
CPT0205670004
Tumor
-0.2
CPT0002410011
Tumor
-0.2
CPT0167970003
Tumor
-0.2
CPT0217880003
Tumor
-0.2
CPT0209440003
Tumor
-0.2
CPT0079790003
Tumor
-0.2
CPT0093360003
Tumor
-0.2
CPT0228220003
Tumor
-0.3
CPT0175060003
Tumor
-0.3
CPT0199770003
Tumor
-0.3
CPT0206330003
Tumor
-0.3
CPT0125510003
Tumor
-0.3
CPT0204360003
Normal
-0.3
CPT0204400003
Normal
-0.3
CPT0087570003
Tumor
-0.3
CPT0204420003
Normal
-0.3
CPT0204350003
Normal
-0.3
CPT0204410003
Normal
-0.3
CPT0216920008
Tumor
-0.4
CPT0204380003
Normal
-0.4
CPT0221180003
Tumor
-0.4
CPT0087730003
Tumor
-0.4
CPT0204370003
Normal
-0.4
CPT0093550003
Tumor
-0.4
CPT0206110003
Tumor
-0.4
CPT0206450003
Tumor
-0.4
CPT0168590003
Tumor
-0.4
CPT0087950003
Tumor
-0.5
CPT0206880003
Tumor
-0.5
CPT0186100003
Tumor
-0.5
CPT0093590003
Tumor
-0.5
CPT0162020003
Tumor
-0.5
CPT0167860004
Tumor
-0.5
CPT0196850003
Tumor
-0.6
CPT0189650004
Tumor
-0.6
CPT0204340003
Normal
-0.7
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.